iSpecimen Inc. Common Stock
ISPCiSpecimen Inc. (ISPC) is a biotechnology company focused on providing a platform that facilitates the procurement of human biospecimens for medical research. Through its digital marketplace, the company connects researchers with a broad network of hospitals, clinics, and tissue banks to expedite the collection and delivery of quality biological samples, supporting advancements in personalized medicine and diagnostics.
Company News
E.F. Hutton & Co. acted as exclusive placement agent for iSpecimen Inc.'s $2.5 million private placement, which closed on May 11, 2026. This marks the second financing transaction between the two companies in six months, following a $5.5 million placement in December 2025. iSpecimen operates an online marketplace connecting researchers with biosp...
iSpecimen Inc. (Nasdaq: ISPC) announced a private placement offering of approximately $2.5 million in gross proceeds. The company will issue 488,281 shares at $5.12 per share, with net proceeds intended for working capital and marketing expenses. The offering is expected to close on May 11, 2026, subject to customary closing conditions and requir...
iSpecimen Inc. (NASDAQ: ISPC) shares surged 56.19% in after-hours trading to $0.20 following the announcement of a direct supplier-to-customer shipping overhaul that reduces domestic transit times by 70-85%, cutting delivery from 7-14 days to 1-2 days. The company also expanded rare specimen sourcing partnerships across Europe. However, the stock...
U.S. stock futures declined on New Year's Eve as hopes for a year-end Santa Claus rally fade. Markets remain jittery following President Trump's threats against Federal Reserve Chair Jerome Powell. Investors await the Initial Jobless Claims report before market open. The S&P 500, Dow Jones, and Nasdaq 100 all traded lower in premarket, with sever...
iSpecimen Inc. (Nasdaq: ISPC), an online marketplace for biospecimens, announced a securities purchase agreement with accredited investors for approximately $5.5 million in gross proceeds. The company will issue 6,875 shares of Series C Convertible Preferred Stock at $800 per share, convertible into common stock at 85% of the closing price. Net p...
